622 related articles for article (PubMed ID: 19463284)
21. The echinocandins: three useful choices or three too many?
Bal AM
Int J Antimicrob Agents; 2010 Jan; 35(1):13-8. PubMed ID: 19942413
[TBL] [Abstract][Full Text] [Related]
22. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
23. [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients].
Pozo-Laderas JC
Rev Iberoam Micol; 2009 Mar; 26(1):69-74. PubMed ID: 19463281
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
Catalán-González M; Carlos Montejo-González J
Rev Iberoam Micol; 2009 Mar; 26(1):23-34. PubMed ID: 19463274
[TBL] [Abstract][Full Text] [Related]
25. Micafungin - the newest echinocandin.
Temesgen Z; Barreto J; Vento S
Drugs Today (Barc); 2009 Jun; 45(6):469-78. PubMed ID: 19856528
[TBL] [Abstract][Full Text] [Related]
26. Micafungin for the treatment of invasive aspergillosis.
Enoch DA; Idris SF; Aliyu SH; Micallef C; Sule O; Karas JA
J Infect; 2014 Jun; 68(6):507-26. PubMed ID: 24480373
[TBL] [Abstract][Full Text] [Related]
27. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
Carter NJ; Keating GM
Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
29. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
30. Micafungin: a therapeutic review.
Higashiyama Y; Kohno S
Expert Rev Anti Infect Ther; 2004 Jun; 2(3):345-55. PubMed ID: 15482200
[TBL] [Abstract][Full Text] [Related]
31. Micafungin: pharmacology, experimental therapeutics and clinical applications.
Groll AH; Stergiopoulou T; Roilides E; Walsh TJ
Expert Opin Investig Drugs; 2005 Apr; 14(4):489-509. PubMed ID: 15882123
[TBL] [Abstract][Full Text] [Related]
32. Micafungin.
Jarvis B; Figgitt DP; Scott LJ
Drugs; 2004; 64(9):969-82; discussion 983-4. PubMed ID: 15101786
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
[TBL] [Abstract][Full Text] [Related]
34. [Role of anidulafungin in solid organ transplant recipients].
Aguado JM; Ayats J
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():29-34. PubMed ID: 19572432
[TBL] [Abstract][Full Text] [Related]
35. A comparative evaluation of properties and clinical efficacy of the echinocandins.
Kim R; Khachikian D; Reboli AC
Expert Opin Pharmacother; 2007 Jul; 8(10):1479-92. PubMed ID: 17661730
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
37. [Echinocandins in invasive candidiasis].
Glöckner A; Cornely OA
Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection.
Hashii Y; Kusuki S; Takizawa S; Tokimasa S; Ohta H; Hara J; Ozono K
Pediatr Int; 2014 Dec; 56(6):834-837. PubMed ID: 24730676
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of micafungin for prophylaxis against invasive fungal infections in Japanese patients undergoing hematopoietic stem cell transplantation: Results of a post-marketing surveillance study.
Kobayashi C; Hanadate T; Niwa T; Hirano Y; Yoshiyasu T; So M; Matsui K
J Infect Chemother; 2015 Jun; 21(6):438-43. PubMed ID: 25749360
[TBL] [Abstract][Full Text] [Related]
40. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
